#ROMVIMZA #Vimseltinib #TGCTtreatment #tenosynovialgiantcelltumour #EU #symptomatictenosynovialgiantcelltumour #TGCT #marketingauthorisation #TGCTtherapy #OnoPharmaceutical #Deciphera #phase3MOTIONstudy #Secondaryendpoints #tumourresponse #stiffness #qualityoflife
pharmatimes.com/news/europea...
pharmatimes.com/news/europea...
European Commission approves ROMVIMZA for TGCT treatment - PharmaTimes
Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU
pharmatimes.com
September 22, 2025 at 8:26 AM